EUROFINS SCIENTIFIC S.E.

ISIN: FR0014000MR3 WKN: - Asset Class: Stock



Company Profile

Eurofins Scientific SE engages in the bio-analytical testing of food, environment, and pharmaceuticals products. The firm offers testing and laboratory services for agro science, genomics, discovery pharmacology and for supporting clinical studies. It operates through the following geographical segments: Europe, North America, and Rest of the World. The company was founded by Gilles G. Martin in 1987 and is headquartered in Luxembourg.

Financial figures, Fiscal year: from 01.01. to 31.12.

| | 2023 | | 2022 | | 2021 | |
|--------------------------------|-------------------------------|----------------|-------------------------------|----------------|-------------------------------|---------------|
| Financial figures | Assets Liabilities and equity | | Assets Liabilities and equity | | Assets Liabilities and equity | |
| Current assets | 3,066,400,000 | | 2,313,300,000 | | 2,319,000,000 | |
| Common stock capital | | 1,900,000 | | 1,900,000 | | 1,900,000 |
| Fixed assets | 7,822,200,000 | | 7,770,200,000 | | 7,013,300,000 | |
| Equity capital of a company | | 4,137,400,000 | | 4,268,300,000 | | 3,677,100,000 |
| Cash and cash equivalents | 749,100,000 | | 432,200,000 | | 497,900,000 | |
| Accrued liabilities | | 87,100,000 | | 78,700,000 | | 91,200,000 |
| Other assets | - | | - | | - | |
| Current liabilities | | 2,121,700,000 | | 1,772,200,000 | | 1,855,800,000 |
| Prepayments and accrued income | - | | - | | - | |
| Non-current liabilities | | 4,629,500,000 | | 4,043,000,000 | | 3,799,400,000 |
| Different income | | - | | - | | - |
| Other liabilities | | 106,800,000 | | 136,200,000 | | 84,300,000 |
| Total assets | 10,888,600,000 | 10,888,600,000 | 10,083,500,000 | 10,083,500,000 | 9,332,300,000 | 9,332,300,000 |

Balance notes

Othors

| | 2023 | 2022 | 2021 |
|---------------------|---------|---------|---------|
| Accounting standard | IFRS | IFRS | IFRS |
| Employees | 61,798 | 61,379 | 57,992 |
| Equity ratio | 38.55% | 43.01% | 39.72% |
| Debt-equity ratio | 159.42% | 132.49% | 151.78% |

| Others | | | |
|------------------|--------|--------|--------|
| | | | |
| | 2023 | 2022 | 2021 |
| Tax Expense Rate | 27.31% | 22.36% | 25.94% |

EUROFINS SCIENTIFIC S.E.

ISIN: FR0014000MR3 WKN: - Asset Class: Stock

Income statement

| 2023 | 2022 | 2021 |
|---------------|---|--|
| 6,514,600,000 | 6,712,100,000 | 6,717,700,000 |
| 310,300,000 | 610,200,000 | 782,600,000 |
| 541,600,000 | 867,400,000 | 1,227,200,000 |
| 422,900,000 | 779,100,000 | 1,054,600,000 |
| 947,300,000 | 1,089,400,000 | 1,342,700,000 |
| -118,700,000 | -88,300,000 | -172,600,000 |
| - | - | - |
| 115,500,000 | 174,200,000 | 273,600,000 |
| 400,000 | 900,000 | 2,000,000 |
| 105,418 | 109,355 | 115,838 |
| | 310,300,000 541,600,000 422,900,000 947,300,000 -118,700,000 - 115,500,000 400,000 | 6,514,600,000 6,712,100,000 310,300,000 610,200,000 541,600,000 867,400,000 422,900,000 779,100,000 947,300,000 1,089,400,000 -118,700,000 -88,300,000 115,500,000 174,200,000 400,000 900,000 |

Board of Directors

| Yves-Loïc Martin | Member of Supervisory Board |
|-------------------|-----------------------------|
| Erica Monfardini | Member of Supervisory Board |
| Evie Roos | Member of Supervisory Board |
| Ivo Rauh | Member of Supervisory Board |
| Pascal Rakovsky | Member of Supervisory Board |
| Patrizia Luchetta | Member of Supervisory Board |
| Valérie Hanote | Member of Supervisory Board |

Members of Management Board

| Gilles Martin | Chairman of Managing Board | |
|-------------------|-------------------------------|--|
| Christian Wurst | Member of Executive Committee | |
| Christopher Hervé | Member of Executive Committee | |
| François Vigneau | Member of Executive Committee | |
| Laurent Lebras | Member of Executive Committee | |
| | | |